CompanyDrug

Chipscreen Biosciences’ CS08399 Wins NMPA Approval – PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas

Policy / Regulatory

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL

Novartis' Cosentyx Wins FDA Pediatric Approval – Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+
CompanyDrug

Novartis’ Cosentyx Wins FDA Pediatric Approval – Only IL-17A Inhibitor for Hidradenitis Suppurativa in Adolescents 12+

CompanyDrug

Cutia Therapeutics’ CU-40105 Wins NMPA Approval – Topical Dutasteride Targets Androgenetic Alopecia with Reduced Systemic Exposure

CompanyDrug

J&J’s Erda-iDRS Shows 89% Complete Response in NMIBC – Intravesical Erdafitinib System Advances to Phase II/III

CompanyDrug

BeBetter Medicine’s Ifupinostat Wins NMPA Approval for PTCL Trial – First HDAC/PI3Kα Dual Inhibitor Enters First-Line Lymphoma Study

CompanyDrug

Abbisko’s Irpagratinib Doses First Patient in Phase II HCC Trial – FGFR4 Inhibitor Plus Toripalimab/Bevacizumab Targets First-Line Liver Cancer

Junshi Biosciences Reports RMB 2.5 Billion 2025 Revenue – Toripalimab Drives 40% Drug Sales Growth as Losses Narrow
Company

Junshi Biosciences Reports RMB 2.5 Billion 2025 Revenue – Toripalimab Drives 40% Drug Sales Growth as Losses Narrow

CompanyDrug

YolTech’s YOLT-202 Wins FDA Phase II/III Approval – In Vivo Base Editing Gene Therapy Targets Alpha-1 Antitrypsin Deficiency

GSK's Arexvy Wins FDA Label Expansion – RSV Vaccine Now Covers High-Risk Adults Aged 18-49
CompanyDrug

GSK’s Arexvy Wins FDA Label Expansion – RSV Vaccine Now Covers High-Risk Adults Aged 18-49

Biogen's Salanersen Shows 75% NfL Reduction in SMA Phase Ib – Once-Yearly ASO Advances to Phase III
CompanyDrug

Biogen’s Salanersen Shows 75% NfL Reduction in SMA Phase Ib – Once-Yearly ASO Advances to Phase III

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market
CompanyDeals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market